Oraverse is a drug owned by Septodont Holding Sas. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 21, 2025. Details of Oraverse's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7575757 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(6 months ago) |
Expired
|
| US7569230 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct, 2023
(2 years ago) |
Expired
|
| US7229630 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jun, 2023
(2 years ago) |
Expired
|
| US6872390 | Local anesthetic methods and kits |
May, 2021
(4 years ago) |
Expired
|
| US6764678 | Local anesthetic methods and kits |
May, 2021
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Oraverse's patents.
Latest Legal Activities on Oraverse's Patents
Given below is the list of recent legal activities going on the following patents of Oraverse.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2021 | US7575757 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2021 | US7569230 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Dec, 2018 | US7229630 |
| Termination or Final Written Decision | 06 Nov, 2016 | US7575757 |
| Petition Requesting Trial | 06 Nov, 2016 | US7575757 |
| Request for Trial Granted in Part | 06 Nov, 2016 | US7575757 |
| Request for Trial Granted
Critical | 08 Jul, 2016 | US7575757 |
| Petition Requesting Trial | 08 Jul, 2016 | US7575757 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 30 Dec, 2010 | US7229630 |
| Recordation of Patent Grant Mailed
Critical | 18 Aug, 2009 | US7575757 |
FDA has granted several exclusivities to Oraverse. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Oraverse, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Oraverse.
Exclusivity Information
Oraverse holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Oraverse's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 18, 2019 |
US patents provide insights into the exclusivity only within the United States, but
Oraverse is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Oraverse's family patents as well as insights into
ongoing legal events
on those patents.
Oraverse's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Oraverse's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 21, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Oraverse Generic API suppliers:
Phentolamine Mesylate is the generic name for the brand Oraverse. 2 different companies have already filed for the generic of Oraverse, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Oraverse's generic
Alternative Brands for Oraverse
Oraverse which is used for reversal of soft-tissue anesthesia following intraoral local anesthetic injection., has several other brand drugs using the same active ingredient (Phentolamine Mesylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Famygen Life Sci |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Phentolamine Mesylate, Oraverse's active ingredient. Check the complete list of approved generic manufacturers for Oraverse
About Oraverse
Oraverse is a drug owned by Septodont Holding Sas. It is used for reversal of soft-tissue anesthesia following intraoral local anesthetic injection. Oraverse uses Phentolamine Mesylate as an active ingredient. Oraverse was launched by Septodont Holding in 2008.
Approval Date:
Oraverse was approved by FDA for market use on 09 May, 2008.
Active Ingredient:
Oraverse uses Phentolamine Mesylate as the active ingredient. Check out other Drugs and Companies using Phentolamine Mesylate ingredient
Treatment:
Oraverse is used for reversal of soft-tissue anesthesia following intraoral local anesthetic injection.
Dosage:
Oraverse is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4MG/1.7ML | INJECTABLE | Prescription | INJECTION |